# NCT04937166 (NCT04937166)

> A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

No report yet. It can be ordered.

- Drugs tested: DSP107 plus azacitidine; DSP107 plus azacitidine plus venetoclax
- Indication: acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04937166
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Kahr Medical
- Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia
- Interventions: DSP107; Azacitidine; Venetoclax
- Enrollment: 25
- Primary outcome: Adverse Events (AEs)
- Primary outcome: Dose Limiting Toxicities (DLT)
- Primary outcome: Response Rate (RR) including Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi)

## Indexed commentary on NCT04937166 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04937166